Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease

Gut

Volumn 54, Issue 11, 2005, Pages 1553-1557

  Van Heel, D A ^a   Ghosh, S ^a   Hunt, K A ^a   Mathew, C G ^b   Forbes, A ^c   Jewell, D P ^d   Playford, R J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ST MARK S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; DNA; INTERLEUKIN 8; MURAMYL DIPEPTIDE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL INTERACTION; CELL MUTANT; CELL STIMULATION; CLINICAL ARTICLE; COLON CROHN DISEASE; CONTROLLED STUDY; CPG ISLAND; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC DISORDER; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; WILD TYPE;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADULT; BLOTTING, WESTERN; CELLS, CULTURED; CPG ISLANDS; CROHN DISEASE; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, MUCOSAL; INTERLEUKIN-8; INTESTINAL MUCOSA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27444444603     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.065888     Document Type: Article

References (33)

1. Philpott DJ, Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004;41:1099-108.
2. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004;99:2393-404.
3. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
4. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
5. van Heel DA, McGovern DPB, Jewell DP. Crohn's disease: genetic susceptibility, bacteria and innate immunity. Lancet 2001;357:1902-4.
6. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.
7. Yang S, Tamai R, Akashi S, et al. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 2001;69:2045-53.
8. Traub S, Kubasch N, Morath S, et al. Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine induction. J Biol Chem 2004;279:8694-700.
9. van Heel D, Ghosh S, Butler M, et al. Muramyl dipeptide and Toll-like receptor sensitivity in NOD2 associated Crohn's disease. Lancet 2005;365:1794-6.
10. Uehara A, Yang S, Fujimoto Y, et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 2005;7:53-61.
11. van Heel D, McGovern D, Cardon L, et al. Fine mapping of the IBD1 locus did not identify Crohn's disease associated NOD2 variants: implications for complex disease genetics. Am J Med Genet 2002;111:253-9.
12. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
13. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-66.
14. Kreher CR, Dittrich MT, Guerkov R, et al. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 2003;278:79-93.
15. Hartmann G, Battiany J, Poeck H, et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003;33:1633-41.
16. Li J, Moran T, Swanson E, et al. Regulation of IL-8 and IL-1 beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 2004;13:1715-25.
17. Jugde F, Boissier C, Birebent B, et al. Stimulation of peripheral blood and intestinal mucosa cells by synthetic CpG oligodeoxynucleotides. Hum Immunol 2004;65:218-30.
18. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.
19. Akhtar M, Watson JL, Nazli A, et al. Bacterial DNA evokes epithelial IL-8 production by a MAPK-dependent, NF-kappaB-independent pathway. FASEB J 2003;17:1319-21.
20. Ogura Y, Lala S, Xin W, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003;52:1591-7.
21. Rumio C, Besusso D, Palazzo M, et al. Degranulation of Paneth cells via toll-like receptor 9. Am J Pathol 2004;165:373-81.
22. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004;4:953-64.
23. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-41.
24. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004;5:800-8.
25. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005;307:734-8.
26. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-4.
27. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-8.
28. Kobayashi K, Inohara N, Hernandez LD, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002;416:194-9.
29. Damiano JS, Oliveira V, Welsh K, et al. Heterotypic interactions among NACHT domains: implications for regulation of innate immune responses. Biochem J 2004;381(Pt 1):213-19.
30. Chen CM, Gong Y, Zhang M, et al. Reciprocal cross talk between Nod2 and TAK1 signaling pathways. J Biol Chem 2004;279:25876-82.
31. Martinon F, Agostini L, Meylan E, et al. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 2004;14:1929-34.
32. Barnich N, Hisamatsu T, Aguirre JE, et al. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem 2005;280:19021-6.
33. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.